A phase 1 clinical study of WT2725 in patients with advanced solid malignancies.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222290

Enrollment

Registered

2013-11-14

Start date

2014-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid malignancies

Interventions

investigational material(s) Generic name etc : WT2725 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: out-patient Main Inclusion criteria - Patients >= 20 year old at informed consent - ECOG performance status: 0 or 1 - Histologically or cytologically diagnosed as solid tumor - Refractory to standard treatment or no standard treatment is established

Exclusion criteria

Exclusion criteria: Main Exclusion criteria - Positive for HIV and HCV antibody, HBV surface antigen within 90 days prior to enrollment - Symptomatic brain metastasis - Previous treatment with WT2725 or WT1 peptide

Design outcomes

Primary

Measure	Time frame
safety Safety - Maximum tolerated dose (MTD) - Adverse Event, side effect - clinical laboratory tests, vital signs measurements, body weight measurements, and electrocardiogram (ECG) results, chest X-ray examination	—

Secondary

Measure	Time frame
efficacy Efficacy Tumor assessment	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026